Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.50 |
| ▸ | BCL2 | P10415 | 2/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | BAD | Q92934 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217366 | 0.89 | PARP15 (0.49) | MCL1BCL2BCL2L1BADGAA | |
| SCHEMBL5218060 | 0.87 | SMN1; SMN2 (0.43) | MCL1L3MBTL1MAPTKDM4EALDH1A1 | |
| SCHEMBL5211065 | 0.85 | EDNRA (0.46) | MCL1GAAMAPTKDM4EALDH1A1 | |
| SCHEMBL5742814 | 0.83 | MEN1 (0.42) | MCL1BCL2BCL2L1BADGAA | |
| SCHEMBL4771788 | 0.81 | MCL1 (0.45) | MCL1BCL2BCL2L1BADMTNR1B | |
| SCHEMBL5214813 | 0.81 | MEN1 (0.40) | MCL1STING1 | |
| SCHEMBL5215287 | 0.79 | LMNA (0.47) | GAAMAPTALDH1A1STING1 | |
| SCHEMBL5210914 | 0.78 | NOX1 (0.44) | GAAL3MBTL1MAPTPKMMTNR1A | |
| SCHEMBL9371330 | 0.78 | EDNRA (0.56) | KDM4EALDH1A1STING1 | |
| SCHEMBL5211173 | 0.77 | STING1 (0.44) | MCL1BCL2BCL2L1BADGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | MCL1 1046/4885BCL2 974/4885BCL2L1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.